000			01502nam a2200133Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aProtein–Ligand Interactions: Target Identification and Drug Discovery
546			_aEnglish[eng]
650			_aserum half-life extension||fatty acid conjugation||FcRn-mediated recycling||serum albumin||translocator protein (TSPO)||CoCl2||mitochondrial membrane potential||reactive oxygen species (ROS)||cell viability||cell death||lung cancer cell line||acetylcholinesterase||amyloid beta aggregation||neuroprotection||molecular docking||multi-target drug||structure–activity relationship||brassicasterol||phytosterols||HSV||Mycobacterium tuberculosis||HSV-1 DNA polymerase||HSV-1 TK||human CDK2||ACE||UDP-galactopyranose mutase||heat shock protein 70||Hsp70||piperine||fluorescence spectroscopy||molecular dynamics||molecular biophysics||GADD45β||MKK7||multiple myeloma||protein-ligand interaction||STD-NMR||sigma receptors||sigma ligands||cancer||SIGMAR1||PGRMC1||TMEM97||NCI60 COMPARE analysis||membrane||lipid-protein interaction||lipid signalling||kinase regulation||phosphatidylinositols||molecular docking simulation||target identification||small-molecule derivatives of salicylanilide||drug discovery||drug development||thyroid diseases||endocrine disruptor compound||human umbilical artery||vascular homeostasis
700			_aAltieri, Fabio
856			_uhttps://mdpi.com/books/pdfview/book/4054
942			_cEB
999			_c27797 _d27797